Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Background Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing capacity of γδ T cells, which are critica...

Full description

Bibliographic Details
Main Authors: Niannian Ji, Neelam Mukherjee, Tyler J Curiel, Ryan M Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Robert S Svatek
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e001941.full

Internet

https://jitc.bmj.com/content/9/3/e001941.full

Similar Items